Kiniksa为KPL-387获得FDA的孤儿药物地位,每月注射一次,用于复发性心肺炎。 Kiniksa gets FDA orphan drug status for KPL-387, a monthly injectable for recurring pericarditis.

Kiniksa制药公司已经获得林业发展局指定为KPL-387的孤儿药品,这是一项可能每月对包括经常病例在内的心肌炎进行次皮下治疗的方案。 Kiniksa Pharmaceuticals has received FDA orphan drug designation for KPL-387, a potential monthly subcutaneous treatment for pericarditis, including recurrent cases. 该药物是针对Interleukin-1受体的单克隆抗体,旨在解决这种罕见情况下未得到满足的需要。 The drug, a monoclonal antibody targeting interleukin-1 receptors, aims to address the unmet need in this rare condition. 该指定提供诸如税收抵免和赠款供资等发展激励措施。 The designation offers development incentives like tax credits and grant funding. 预计到2026年底将取得第二阶段试验结果。 Phase 2 trial results are expected by late 2026.